Open AccessReview
Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient
Received: 18 October 2013 / Revised: 16 December 2013 / Accepted: 24 December 2013 / Published: 30 December 2013
Viewed by 1758 | PDF Full-text (191 KB) | HTML Full-text | XML Full-text
Abstract
Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well
[...] Read more.
Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primarily with immunosuppressive therapy. Herein, we review the current literature, detailing the promise and pitfalls of the recommended immunosuppressive therapy for these challenging diseases.
Full article